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Purpose: The aim of this study was to elicit possible differences in prognoses and clinicopathological
factors in pancreatic head cancer with and without obstructive jaundice at diagnosis.
Methods: The data from 169 patients with pancreatic head cancer were retrospectively analyzed.
Results: Patients were divided into two groups according to serum total bilirubin at diagnosis: 3 mg/dL
for icteric group and <3 mg/dL for non-icteric group. In all cases, icteric group (n ¼ 104) had a signiﬁ-
cantly worse prognosis than non-icteric group (n ¼ 65) (median survival time (MST), 7.5 months (M) vs.
13.5 M, respectively; P ¼ 0.049). In 84 resectable cases, icteric group had a signiﬁcantly worse prognosis
than non-icteric group (MST, 14.2 M vs. 20.9 M, respectively; P ¼ 0.049) after almost equivalent treat-
ment intensities. Icteric group had signiﬁcantly larger T- and N-factors according to the UICC Classiﬁ-
cation compared to non-icteric group. The total number of lymph node metastases in icteric group was
signiﬁcantly larger than in non-icteric group (P ¼ 0.008). The intrapancreatic nerve invasion in icteric
group was signiﬁcantly stronger than in non-icteric group (P ¼ 0.016). There were no signiﬁcant dif-
ferences in the mortality and morbidity between icteric and non-icteric groups. In 85 unresectable cases,
there was no signiﬁcant difference between the survival periods of icteric and non-icteric groups (MST,
5.2 M vs. 5.3 M, respectively).
Conclusions: The presence of obstructive jaundice at diagnosis in patients with pancreatic head cancer
may predict an unfavorable survival compared to such patients without obstructive jaundice.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Pancreatic head cancer present as two clinically different phe-
notypes at diagnosis: patients with and without obstructive jaun-
dice. This difference may be partly caused by the location of the
tumor in relation to the intrapancreatic common bile duct. Other
assumable triggers of obstructive jaundice are large tumor size and
a greater degree of invasion.
Recently, the impact of preoperative biliary drainage (PBD) for
icteric periampullary tumor on mortality and morbidity after
pancreaticoduodenectomy (PD) has been well investigated.1e8
Some investigators prefer PBD prior to PD because of its effects
on surgical outcome or survival.2,3,5 However, some investigators
have demonstrated that infectious complications, notably wound
infections, increase with PBD. They have therefore concluded
that immediate PD is preferable, and PBD before PD should be
selectively applied to patients suffering from cholangitis, patients
who will receive neoadjuvant treatments, patients requiring a: þ81 6 6646 6450.
ata).
ciates Ltd. Published by Elsevier Ltsubstantial time of preoperative assessment and operation
schedule, or patients who need additional time for referral to a high
volume center for PD.6e8
Regarding the impact of PBD on survival in patients with
pancreatic head cancer who underwent PD, a few investigations
have been reported. Smith and co-workers were the ﬁrst to
investigate this subject, and concluded that there were no differ-
ences in overall survival between groups who did and did not
receive PBD.9 Eshuis and colleagues reported that a delay in surgery
associated PBD for patients with pancreatic head cancer did not
affect the survival rate.5
The aim of the present study was to compare survival time and
clinicopathological characteristics of patients between icteric and
non-icteric pancreatic head cancer at diagnosis, apart from the
impact of PBD on survival. This study included the unresectable
cases besides the resectable cases.
2. Patients and methods
2.1. Patients
One hundred sixty nine consecutive patients with pancreatic head cancer
admitted in Osaka City University Hospital from January 1990 to December 2009. Nod. All rights reserved.
Table 1
Comparison of treatment for all patients with pancreatic head cancer between
groups stratiﬁed by serum total bilirubin at diagnosis (n ¼ 169).
Characteristics Serum total bilirubin at
diagnosis (mg/dL)
P-value
3
(Icteric group)
<3
(Non-icteric
group)
Number of patients 104 65
Age (years) 65.1  10.4
(34e90)
66.2  10.5
(40e84)
0.512*
Male:Female 63:41 39:26 0.941**
Resectability 47.1% 53.8% 0.395**
Biliary drainage
No 0 65 <0.001**
PTCD 85 0
ERBD 19 0
Serum total bilirubin at
diagnosis (mg/dL)
11.4  7.1
(3.0e44.8)
0.8  0.5
(0.3e2.2)
<0.001*
Gemcitabine No:Yes 67:37 49:16 0.135**
5-Fluoropyrimidine No:Yes 71:33 36:29 0.090**
Radiation therapy No:Yes 76:28 40:25 0.116**
PTCD, percutaneous transhepatic cholangio-drainage; ERBD, endoscopic retrograde
biliary drainage.
Numbers in parentheses are the ranges of values.
P-value was examined by the *Student’s t-test or **chi-square test (Fisher’s exact
test).
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this study. The median follow up time for these patients were 8.8 months (0.3e122
months). The cases included 84 resectable and 85 unresectable tumors. All 84 pa-
tients with resectable pancreatic head cancer in the present study had no hema-
togenous metastasis or peritoneal disseminations, and underwent PD. PD included
pylorus-preserving PD and subtotal stomach-preserving PD.10 Other resectable cri-
terion for pancreatic head cancer beside no distant metastasis is no invasion to
celiac/superior mesenteric/common hepatic artery. Portal invasion is not an unre-
sectable criterion in our institute as well as most Japanese Department of Pancreatic
Surgery. In order to observe survival time, patients whowere admitted after January
2010 were not included in the present study.
2.2. Classiﬁcation
Jaundice was deﬁned as a serum bilirubin level 3 mg/dL, because patients
above this value usually exhibited clinically evident jaundice through ﬁndings of
yellowish skin and/or conjunctival membranes over the sclerae due to hyper-
bilirubinemia. Patients in the present study were therefore divided into two groups:
those with a serum total bilirubin 3 mg/dL at diagnosis (icteric group) and those
with a serum total bilirubin <3 mg/dL at diagnosis (non-icteric group). Among 65
patients of non-icteric group, 15 patients complained abdominal pain, 10 did back
pain, six did appetite loss, and six did weight loss. Among 28 patients with no
complains in non-icteric group, one patient was diagnosed for pancreatic cancer by
medical checkup, and others were done during following up for other diseases such
as diabetes mellitus, chronic pancreatitis, and hepatic hemangioma. Patients in non-
icteric group were diagnosed for pancreatic cancer ﬁrstly with abdominal ultraso-
nography or abdominal computed tomography.
T- andN-factorswere decided according to the International UnionAgainst Cancer
(UICC) Classiﬁcation.11 The deﬁnition of residual tumor after PDwasmade through the
Japanese Pancreas Society’s Classiﬁcation of Pancreatic Cancer12; R0, no residual tu-
mor; R1, microscopic residual tumor; R2, macroscopic residual tumor. The deﬁnitions
of lymphatic invasion (ly), venous invasion (v), and intrapancreatic nerve invasion (ne)
were also made through the Japanese Pancreas Society’s Classiﬁcation of Pancreatic
Cancer; ly0, v0 and ne0meanno invasion; ly1, v1 and ne1mean slight invasion; ly2, v2
and ne2 mean moderate invasion; ly3, v3 and ne3 mean marked invasion.
2.3. Biliary drainage
With serumtotal bilirubin3mg/dLdue to aperiampullary tumor, biliary drainage
(BD) is principally indicated for obstructive jaundice in our institution. Therefore, all
patients in icteric group underwent BD. In our hospital, BD had been performed
through percutaneous transhepatic cholangio-drainage (PTCD). Since 2006, most pa-
tients in our hospital have undergone endoscopic retrograde biliary drainage (ERBD)
for BD. Among 12 patients who underwent BD in our hospital from January 2006 to
December 2009, ERBD were successfully performed for 10 patients and PTCD were
done for two patients. In the most of other hospitals, PTCD has still been performed as
ﬁrst choice treatment for the patients with obstructive jaundice before referring them
to our hospital, because these hospitals had no endoscopists who could perform ERBD.
2.4. Statistical analysis
The Student’s t-test was employed to compare the mean values between icteric
and non-icteric groups. The chi-square test (or Fisher exact test)was used to compareFig. 1. KaplaneMeier curve of patients with all patients with pancreatic head cancer
stratiﬁed by serum total bilirubin at diagnosis (C, 3 mg/dL vs. ,, <3 mg/dL). MST,
median survival time.the prevalence or distribution of two variables. Correlation was evaluated by the
Spearman’s rank correlation test. Survival datawere estimated by the KaplaneMeier
method and examined by the log-rank test as a univariate survival analysis. The Cox
proportional hazard model was employed for the multivariate analysis of survival. A
P-value <0.05 was considered to indicate statistical signiﬁcance.
3. Results
3.1. All case
The survival time of icteric group was signiﬁcantly shorter than
that of non-icteric group in 169 patients with pancreatic head
cancer (Fig. 1). There were no signiﬁcant differences in back ground
characteristics (Table 1).
3.2. Resectable case
The survival time of icteric group was signiﬁcantly shorter than
that of non-icteric group in resectable pancreatic head cancerFig. 2. KaplaneMeier curve of patients with resectable pancreatic head cancer who
underwent pancreaticoduodenectomy stratiﬁed by serum total bilirubin at diagnosis
(C, 3 mg/dL vs.,, <3 mg/dL). MST, median survival time.
Table 2
Comparison of treatment for patients with resectable pancreatic head cancer between groups stratiﬁed by serum total bilirubin at diagnosis (n ¼ 84).
Characteristics Serum total bilirubin at diagnosis (mg/dL) P-value
3
(Icteric group)
<3
(Non-icteric group)
Number of patients 49 35
Age (years) 65.2  11.0 (34e82) 66.4  10.0 (40e84) 0.626*
Male:Female 26:23 20:15 0.711**
Preoperative biliary drainage
No 0 35 <0.001**
PTCD 39 0
ERBD 10 0
Serum total bilirubin at diagnosis (mg/dL) 11.6  6.8 (3.0e30.5) 0.8  0.5 (0.3e2.2) <0.001*
Total bilirubin at 1 day before operation (mg/dL) 1.5  1.0 (0.3e4.9) 0.7  0.4 (0.2e1.9) <0.001*
Operation PD:PpPD:SSPPD 45:2:2 30:2:3 0.640**
Portal vein resection No:Yes 33:16 24:11 0.906**
Operation time (min) 493  118 (285e925) 525  174 (345e1350) 0.316*
Intraoperative blood loss volume (mL) 1628  1094 (430e5710) 1838  3473 (300e21,300) 0.693*
Intraoperative blood transfusion No:Yes 16:33 12:23 >0.999**
Intraoperative blood transfusion volume (mL) 1697  1359 (0e7080) 1816  4312 (0e21,560) 0.878*
Adjuvant gemcitabine No:Yes 44:5 32:3 >0.999**
Adjuvant 5-ﬂuoropyrimidine No:Yes 31:18 18:17 0.278**
Intraoperative irradiation No:Yes 40:9 33:2 0.111**
Extracorporal irradiation No:Yes 45:4 33:2 >0.999**
PTCD, percutaneous transhepatic cholangio-drainage; ERBD, endoscopic retrograde biliary drainage; PD, pancreaticoduodenectomy; PpPD, pylorus-preserving PD; and SSPPD,
subtotal stomach-preserving PD.
Numbers in parentheses are the ranges of values.
P-value was examined by the *Student’s t-test or **chi-square test (Fisher’s exact test).
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portal vein resection, operation time, or intraoperative blood loss/
transfusion volumes between icteric and non-icteric groups.
Adjuvant chemotherapy and radiation therapy were not different
between the two groups (Table 2). Possible reasons for the poorer
prognosis in icteric group were sought through examination of the
differences in clinicopathological factors between icteric and non-Table 3
Comparison of tumor progression at operation and recurrence site after operation in patie
bilirubin at diagnosis (n ¼ 84).
Characteristics Serum total bilir
3
(Icteric group)
Tumor size (cm) 3.2  1.0 (1.2e5
T-factor T1:T2:T3:T4 1:0:46:2
N-factor N0:N1 14:35
Residual tumor after operation R0:R1:R2 30:5:14
Histology
Well differentiated tubular adenocarcinoma 17
Moderately differentiated tubular adenocarcinoma 23
Poorly differentiated tubular adenocarcinoma 6
Papillary adenocarcinoma 1
Moderately differentiated adenosquamous carcinoma 0
Mucinous carcinoma 1
Undifferentiated carcinoma 1
Total number of lymph node metastases 3.0  3.8 (0e19
Venous invasion v0:v1:v2:v3 29:12:6:2
Lymphatic invasion ly0:ly1:ly2:ly3 7:12:28:2
Intrapancreatic nerve invasion ne0:ne1:ne2:ne3 6:10:22:11
Recurrence site
Peritoneum No:Yes 31:18
Liver No:Yes 34:15
Local No:Yes 37:12
Lymph node No:Yes 41:8
Lung No:Yes 46:3
Bone No:Yes 47:2
TNM classiﬁcation is according to the International Union Against Cancer (UICC, 2009).
R-, v-, ly-, and ne-factors are expressed according to the Classiﬁcation of Pancreatic Carc
Patients who had multiple recurrence sites were included in each recurrence site.
P-value wad examined by the *Student’s t-test, the **chi-square test (Fisher’s exact test)
r-value was calculated by the #Spearman’s rank correlation test.icteric groups (Table 3). The tumor size between the two groups
was not different. The T- and N-factors of icteric group were
signiﬁcantly larger than those of non-icteric group. The degree of
residual tumor after operation for icteric group tended to be higher
than that for non-icteric group. There were no differences in his-
tology between icteric and non-icteric groups. The total number of
lymph node metastases in icteric group was signiﬁcantly highernts with resectable pancreatic head cancer between groups stratiﬁed by serum total
ubin at diagnosis (mg/dL) P-value r-value
<3
(Non-icteric group)
.0) 2.9  1.1 (1.0e5.5) 0.181* e
1:8:24:2 0.013# 0.272#
20:15 <0.009** e
28:3:4 <0.055# 0.211#
11 0.639** e
20
2
0
1
1
0
) 1.1  2.2 (0e9) 0.008* e
27:7:1:0 0.054# 0.212#
11:8:13:3 0.165# 0.152#
11:10:9:5 0.016# 0.264#
26:9 0.286** e
30:5 0.083** e
27:8 0.863** e
27:8 0.452** e
33:2 >0.999** e
34:1 >0.999** e
inoma by the Japanese Pancreas Society (2003).
or the #Spearman’s rank test.
Table 5
Comparison of in-hospital postoperative mortality and morbidity in patients with
pancreatic head cancer between groups stratiﬁed by serum total bilirubin at diag-
nosis (n ¼ 84).
Characteristics Serum total bilirubin at diagnosis
(mg/dL)
P-value
3
(Icteric group)
<3
(Non-icteric group)
Number of patients 49 35 e
In-hospital postoperative
mortality No:Yes
47:2 33:2 >0.999
Reoperation No:Yes 46:3 34:1 0.637
Postoperative complication
Pacreaticojejunostomy
leakage No:Yes
48:1 33:2 0.568
Choledochojejunostomy
leakage No:Yes
46:3 35:0 0.262
Gastrojejunal bleeding
No:Yes
47:2 33:2 >0.999
Intraabdominal bleeding
No:Yes
48:1 35:0 >0.999
Cholangitis No:Yes 45:4 33:2 >0.999
Ileus No:Yes 47:2 35:0 0.508
Pneumonia No:Yes 45:4 33:2 >0.999
P-value was examined by the chi-square test (Fisher’s exact test).
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invasion of icteric group was signiﬁcantly larger than those of non-
icteric group. There were no speciﬁc recurrence sites for icteric or
non-icteric groups except for inclination toward a higher rate of
liver metastatic recurrence in icteric group compared to non-icteric
group.
Univariate survival analysis indicated that icteric group, T4, N1,
R1/2, and ne2/3 were signiﬁcant predictors of aworse prognosis for
patients with pancreatic head cancer who underwent PD (Table 4).
By multivariate survival analysis, the factors of R1/2 alone were
shown to have an independent prognostic impact on survival
(Table 4).
Postoperative mortality and morbidity after PD between icteric
and non-icteric groups were compared (Table 5). Two patients in
both icteric and non-icteric groups died during their hospitalization
after PD. Therewas no statistical difference in the rate of in-hospital
mortality or reoperation between icteric and non-icteric groups.
Regarding postoperative complications such as pancreaticojej-
unostomy leakage, choledochojejunostomy leakage, gastrojejunal
bleeding, intraabdominal bleeding, cholangitis, ileus, and pneu-
monia, there were no statistical differences in incident rates be-
tween icteric and non-icteric groups.
3.3. Unresectable case
There was no difference of survival time between icteric and
non-icteric groups in unresectable pancreatic head cancer (Fig. 3).
There were no signiﬁcant differences in inoperable factors such as
involvement of superior mesenteric/celiac artery and distant
metastasis. Regarding palliative operation, chemotherapy and ra-
diation therapy, there were no differences between the two groups
(Table 6).
4. Discussion
The primary purpose of this study was to examine the capability
to predict survival time through the presence of obstructive jaun-
dice at diagnosis in patients with pancreatic head cancer. Median
survival time of 104 patients belonged to icteric group was signif-
icantly shorter than that of 65 patients belonged to non-icteric
group under similar resectability and treatment backgrounds
(Fig. 1, Table 1). These results suggest the icteric patients with
pancreatic head cancer may have worse prognosis compared to
those with non-icteric patients. It is notable that the resectability
was not different between icteric and non-icteric groups.
It is well known that there is a large difference between the
survival times of resectable and unresectable patients with
pancreatic head cancer. Therefore, the survival data should beTable 4
Univariate and multivariate survival analysis of patients with resectable pancreatic head
Variable Comparison Univariate
No. of patients
Serum total bilirubin at diagnosis 3 mg/dL vs. <3 mg/dL
(Icteric group) vs.
(Non-icteric group)
49:35
T-factor T4 vs. T1, 2, 3 4:80
N-factor N1 vs. N0 50:34
Residul tumor after operation R1, 2 vs. R0 26:58
Intrapancreatic nerve invasion ne2, 3 vs. ne0, 1 47:37
*P-values were examined by the log-rank test for univariate survival analysis.
**P-values were examined by the Cox proportional hazards model for multivariate survi
TNM classiﬁcation is according to the International Union against Cancer (UICC, 2009).
R-and ne-factors are expressed according to the Classiﬁcation of Pancreatic Carcinoma banalyzed respectively in resectable and unresectable cases. Uni-
variate analysis indicated a signiﬁcantly poorer prognosis in icteric
group compared to non-icteric group in resectable patients with
the comparable treatment backgrounds (Fig. 2, Table 2). Contrary to
our expectation, there was no signiﬁcant difference in tumor size
between the two groups (Table 3). The unfavorable prognosis of
icteric group may be caused by the signiﬁcantly larger T- and N-
factors and the signiﬁcantly stronger intrapancreatic nerve invasion
compared to non-icteric group (Table 3). R-factor and venous in-
vasion of icteric group tended to be higher than those of non-icteric
group (Table 3). Actually, larger T-, N-, R-factors and stronger
intrapancreatic nerve invasion were signiﬁcant predictors of a
worse prognosis by univariate survival analysis in the present study
(Table 4). The previous investigations also have demonstrated that
these factors were signiﬁcant prognostic indicators.13e15 However,
by multivariate survival analysis, icteric group failed to be an in-
dependent predictor of worse survival in the present study
(Table 4). The relatively higher rate of recurrence in the liver in
icteric group compared to non-icteric group may also be attributed
to the higher degrees of T- and N-factors and stronger intra-
pancreatic nerve invasion in icteric group (Table 3). These ﬁndings
are summarized as that resectable pancreatic head cancer with
obstructive jaundice preoperatively may have severer advanced
tumor than non-icteric case. Consequently, the patient withcancer who underwent pancreaticoduodenectomy (n ¼ 84).
Multivariate
Median survival
(months)
P-value* Hazard ratio 95% conﬁdence
interval
P-value**
14.2:20.9 0.049 1.149 0.675e1.954 0.610
2.9:17.9 0.001 2.124 0.712e6.339 0.177
15.0:22.8 0.018 1.394 0.814e2.390 0.226
8.3:20.7 <0.001 2.594 1.496e4.499 <0.001
14.0:20.9 0.019 1.541 0.918e2.587 0.102
val analysis.
y the Japanese Pancreas Society (2003).
Fig. 3. KaplaneMeier curve of patients with unresectable pancreatic head cancer
stratiﬁed by serum total bilirubin at diagnosis (C, 3 mg/dL vs.,, <3 mg/dL). Median
survival time: C, 5.2 months; ,, 5.3 months.
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may be a candidate for intensive treatment such as neoadjuvant
treatment.
The rates of in-hospital mortality and reoperation in icteric
group were not different from those of non-icteric group. Occur-
rence of life-threatening complications after PD was also not
different between the two groups (Table 5). These results coincided
with the previous ﬁndings that PBD was not associated with mor-
tality andmorbidity after PD,1e4 because all patients of icteric group
underwent PBD in the present study. A recent randomized trial
comparing the clinical outcomes of PBD to those of early-surgery
without PBD for patients with pancreatic head cancer who devel-
oped obstructive jaundice indicated no signiﬁcant differences of
surgery-related complications, mortality or the length of hospital
stay between the two groups. However, the authors concluded that
routine PBD for patients with pancreatic head cancer undergoingTable 6
Comparison of inoperable factor and treatment for patients with unresectable pancreatic
Characteristics Serum total
3
(Icteric grou
Number of patients 55
Age (years) 65.0  9.9 (5
Male:Female 37:18
Biliary drainage
No 0
PTCD 46
ERBD 9
Serum total bilirubin at diagnosis (mg/dL) 11.2  7.5 (3
Peritoneal dissemination No:Yes 45:10
Hepatic metastasis No:Yes 26:29
Invasion to superior mesenteric/celiac artery No:Yes 27:28
Para-aorta/Virchow lymph node metastasis No:Yes 48:7
Pulmonary metastasis No:Yes 52:3
Bone metastasis No:Yes 54:1
Choledocho-duodenal/jejunal anastomosis No:Yes 47:8
Gastrojejunal anastomosis No:Yes 45:10
Gemcitabine No:Yes 30:25
5-Fluoropyrimidine No:Yes 41:14
Radiation therapy No:Yes 40:15
PTCD, percutaneous transhepatic cholangio-drainage; ERBD, endoscopic retrograde bilia
Numbers in parentheses are the ranges of values.
P-value was examined by the *Student’s t-test or **chi-square test (Fisher’s exact test).PD should be avoided because of the high rate of PBD-related
complications (such as cholangitis, pancreatitis, duodenal perfo-
ration and hemorrhage after ERCP).1 A majority of the most recent
retrospective studies of patients with periampullary tumors and
jaundice have demonstrated that there are no signiﬁcant differ-
ences in mortality or morbidity after PD between patients with PBD
andwithout PBD.2e4 In those previous studies, all or the majority of
the non-PBD patients exhibited high serum total bilirubin levels.
This could be because the aim of those investigations was to
examine the necessity of PBD for preoperative jaundice.1e9 It is
notable and distinguishable from the previous studies that all of the
non-PBD patients in the present study had low serum total bili-
rubin levels less than 3 mg/dL.
Contrary to resectable cases, there was no survival difference
between icteric and non-icteric groups in unresectable pancreatic
head cancer (Fig. 3, Table 6). Unresectable patients have intensive
locally advanced tumors and/or distant metastases at diagnosis and
extremely short survival times both in icteric and non-icteric
groups. Although the degrees of T-factor, N-factor, and intra-
pancreatic nerve invasion can not be assessed accurately in unre-
sectable cases, these factors might be not different between icteric
and non-icteric groups, resulting no survival difference.
In conclusion, the patients with pancreatic head cancer andwith
obstructive jaundice at diagnosis may have a worse prognosis
compared to those patients without obstructive jaundice. In the
subgroup analyses, a signiﬁcant survival difference between icteric
and non-icteric patients was seen in resectable cases, but not in
unresectable cases. The worse prognosis of icteric patient after PD
may be due to stronger tumor aggressiveness compared to non-
icteric patient. Because PBD may not increase in-hospital death or
the number of severe surgical complications after PD, patients with
obstructive jaundice may beneﬁt from intensive treatment
including a neoadjuvant chemoradiotherapy after PBD.
Ethical approval
Written consents were obtained from the patients.
Funding
None.head cancer between groups stratiﬁed by serum total bilirubin at diagnosis (n ¼ 85).
bilirubin at diagnosis (mg/dL) P-value
p)
<3
(Non-icteric group)
30
4e90) 65.9  11.3 (40e79) 0.682*
19:11 0.714**
30 <0.001**
0
0
.0e44.8) 0.8  0.6 (0.4e1.6) <0.001*
22:8 0.360**
15:15 0.810**
11:19 0.271**
28:2 0.483**
28:2 >0.999**
30:0 >0.999**
29:1 0.150**
21:9 0.211**
19:11 0.433**
18:12 0.164**
19:11 0.369**
ry drainage.
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